mPEG-PLGA from PolySciTech used in delivery of mRNA for treatment of breast cancer

Triple-negative breast cancer references a specific type of cancer which does not express common cancer receptors such as Herceptin. This makes treatment of this kind of cancer very difficult. Recently, researchers at University of Ottawa, National Research Council Canada used mPEG-PLGA (cat# AK010) PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create nanoparticles for delivery of mRNA. This research holds promise to provide for improved cancer therapy in the future. Read more: El-Sahli, Sara, Shireesha Manturthi, Emma Durocher, Yuxia Bo, Alexandra Akman, Christina Sannan, Melanie Kirkby et al. "Nanoparticle-Mediated mRNA Delivery to Triple-Negative Breast Cancer (TNBC) Patient-Derived Xenograft (PDX) Tumors."?ACS Pharmacology & Translational Science?(2025). https://pubs.acs.org/doi/abs/10.1021/acsptsci.4c00597

“mRNA-based therapies can overcome several challenges faced by traditional therapies in treating a variety of diseases by selectively modulating genes and proteins without genomic integration. However, due to mRNA’s poor stability and inherent limitations, nanoparticle (NP) platforms have been developed to deliver functional mRNA into cells. In cancer treatment, mRNA technology has multiple applications, such as restoration of tumor suppressors and activating antitumor immunity. Most of these applications have been evaluated using simple cell-line-based tumor models, which failed to represent the complexity, heterogeneity, and 3D architecture of patient tumors. This discrepancy has led to inconsistencies and failures in clinical translation. Compared to cell line models, patient-derived xenograft (PDX) models more accurately represent patient tumors and are better suitable for modeling. Therefore, for the first time, this study employed two different TNBC PDX tumors to examine the effects of the mRNA-NPs. mRNA-NPs are developed using EGFP-mRNA as a model and studied in TNBC cell lines, ex vivo TNBC PDX organotypic slice cultures, and in vivo TNBC PDX tumors. Our findings show that NPs can effectively accumulate in tumors after intravenous administration, protecting and delivering mRNA to PDX tumors with different genetic and chemosensitivity backgrounds. These studies offer more clinically relevant modeling systems for mRNA nanotherapies in cancer applications. Keywords: nanoparticles mRNA delivery gene restoration TNBC patient-derived xenograft Cancer Cancer therapy Cells Imaging probes Tumors”

mPEG-PLGA (Cat# AK010): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK010#h

Akina, Inc. launches new GMP manufacturing service available to outside customers https://www.akinainc.com/midwestgmp/

Corbion Purasorb? Polymers: https://akinainc.com/polyscitech/products/purasorb/

Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/